- Recommendations on Prophylaxis and Therapy for Disseminated Mycobacterium avium Complex for Adults and Adolescents Infected with Human Immunodeficiency Virus. Mycobacterium avium complex (MAC) causes disseminated disease in up to 40% of patients with advanced human immunodeficiency virus (HIV) disease in the United States.
- Dose Adjustments. Therapeutic Drug Monitoring:-The value of monitoring plasma concentrations in patients with epilepsy or bipolar disorder has not been established; dosing should be based on therapeutic response. Concomitant use with Known Glucuronidation Inhibitors/Inducers.
Generic name: LITHIUM CARBONATE 300mg
Dosage form: tablet, film coated, extended release
You may refer to Martindale and/or Goodman & Gilman textbooks on pharmacology to find the lowest therapeutic doses. You may also use lowest marketed dose in place of minimum/lowest therapeutic dose. Refer to the article suggested by MAC and use the formulae to determine CV limits.
Medically reviewed by Drugs.com. Last updated on Feb 7, 2020.
- Dosage
Acute Mania
Optimal patient response can usually be established with 1800 mg/day in the following dosages:
1Can also be administered on 600 mg TID recommended dosing interval. | ||
ACUTE MANIA 1.2 operations with rational numbersmr. macs page. | ||
Morning | Afternoon | Nighttime |
LITHOBID® | 3 tabs | 3 tabs |
Such doses will normally produce an effective serum lithium concentration ranging between 1.0 and 1.5 mEq/L. Dosage must be individualized according to serum concentrations and clinical response. Regular monitoring of the patient's clinical state and of serum lithium concentrations is necessary. Serum concentrations should be determined twice per week during the acute phase, and until the serum concentrations and clinical condition of the patient have been stabilized.
Long-Term Control
Desirable serum lithium concentrations are 0.6 to 1.2 mEq/L which can usually be achieved with 900 to 1200 mg/day. Dosage will vary from one individual to another, but generally the following dosages will maintain this concentration:
1Can be administered on TID recommended dosing interval up to 1200 mg/day. | ||
LONG-TERM CONTROL | ||
Morning | Afternoon | Nighttime |
LITHOBID® Extended-Release Tablets1 | 2 tabs (600 mg) | 2 tabs (600 mg) |
Serum lithium concentrations in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months. Patients abnormally sensitive to lithium may exhibit toxic signs at serum concentrations of 1.0 to 1.5 mEq/L. Geriatric patients often respond to reduced dosage, and may exhibit signs of toxicity at serum concentrations ordinarily tolerated by other patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Minimum Therapeutic Dose For Macrobid
Important Considerations
Minimum Therapeutic Dose For Macular Degeneration
- •
- Blood samples for serum lithium determinations should be drawn immediately prior to the next dose when lithium concentrations are relatively stable (i.e., 8 to 12 hours after previous dose). Total reliance must not be placed on serum concentrations alone. Accurate patient evaluation requires both clinical and laboratory analysis.
- •
- LITHOBID® Extended-Release Tablets must be swallowed whole and never chewed or crushed.
Frequently asked questions
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Optimal patient response can usually be established with 1800 mg/day in the following dosages:
1Can also be administered on 600 mg TID recommended dosing interval. | ||
ACUTE MANIA 1.2 operations with rational numbersmr. macs page. | ||
Morning | Afternoon | Nighttime |
LITHOBID® | 3 tabs | 3 tabs |
Such doses will normally produce an effective serum lithium concentration ranging between 1.0 and 1.5 mEq/L. Dosage must be individualized according to serum concentrations and clinical response. Regular monitoring of the patient's clinical state and of serum lithium concentrations is necessary. Serum concentrations should be determined twice per week during the acute phase, and until the serum concentrations and clinical condition of the patient have been stabilized.
Long-Term Control
Desirable serum lithium concentrations are 0.6 to 1.2 mEq/L which can usually be achieved with 900 to 1200 mg/day. Dosage will vary from one individual to another, but generally the following dosages will maintain this concentration:
1Can be administered on TID recommended dosing interval up to 1200 mg/day. | ||
LONG-TERM CONTROL | ||
Morning | Afternoon | Nighttime |
LITHOBID® Extended-Release Tablets1 | 2 tabs (600 mg) | 2 tabs (600 mg) |
Serum lithium concentrations in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months. Patients abnormally sensitive to lithium may exhibit toxic signs at serum concentrations of 1.0 to 1.5 mEq/L. Geriatric patients often respond to reduced dosage, and may exhibit signs of toxicity at serum concentrations ordinarily tolerated by other patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Minimum Therapeutic Dose For Macrobid
Important Considerations
Minimum Therapeutic Dose For Macular Degeneration
- •
- Blood samples for serum lithium determinations should be drawn immediately prior to the next dose when lithium concentrations are relatively stable (i.e., 8 to 12 hours after previous dose). Total reliance must not be placed on serum concentrations alone. Accurate patient evaluation requires both clinical and laboratory analysis.
- •
- LITHOBID® Extended-Release Tablets must be swallowed whole and never chewed or crushed.
Frequently asked questions
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Lithobid (lithium)
- During Pregnancy or Breastfeeding
Consumer resources
Other brands:Eskalith, Eskalith-CR